Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions, such as inflammation. It is actually well known that this enzyme exists under two forms: COX-1 and COX-2. Both enzymes are sensitive to inhibition by conventional non-steroidal anti-inflammatory drugs (NSAIDs). Observations that COX-1 was involved in several homeostatic processes, while COX-2 expression was associated with inflammation and other pathologies, such as cancer proliferation, have led to the development of COX-2 selective inhibitors to improve the therapeutic potency and to reduce the classical side effects associated with the use of conventional NSAIDs. A large number of patents concerning COX inhibition are claimed each year and this article reviews patents claimed during the period January 1998 to December 2001.

Advances in the field of COX-2 inhibition / De Leval, X; Julémont, F; Delarge, J; Sanna, Vanna Annunziata; Pirotte, B; Dogné, J. M.. - In: EXPERT OPINION ON THERAPEUTIC PATENTS. - ISSN 1354-3776. - 12:7(2002), pp. 969-989. [10.1517/13543776.12.7.969]

Advances in the field of COX-2 inhibition

SANNA, Vanna Annunziata;
2002-01-01

Abstract

Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions, such as inflammation. It is actually well known that this enzyme exists under two forms: COX-1 and COX-2. Both enzymes are sensitive to inhibition by conventional non-steroidal anti-inflammatory drugs (NSAIDs). Observations that COX-1 was involved in several homeostatic processes, while COX-2 expression was associated with inflammation and other pathologies, such as cancer proliferation, have led to the development of COX-2 selective inhibitors to improve the therapeutic potency and to reduce the classical side effects associated with the use of conventional NSAIDs. A large number of patents concerning COX inhibition are claimed each year and this article reviews patents claimed during the period January 1998 to December 2001.
2002
Advances in the field of COX-2 inhibition / De Leval, X; Julémont, F; Delarge, J; Sanna, Vanna Annunziata; Pirotte, B; Dogné, J. M.. - In: EXPERT OPINION ON THERAPEUTIC PATENTS. - ISSN 1354-3776. - 12:7(2002), pp. 969-989. [10.1517/13543776.12.7.969]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/150209
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact